What are the pros and cons of using Simponi Aria (golimumab) infusions versus Otezla (apremilast) for a patient with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis?

Simponi Aria vs Otezla: Comparative Analysis

For patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, Simponi Aria (golimumab IV) is the superior choice when targeting remission or low disease activity, as TNF inhibitors demonstrate stronger efficacy in controlling inflammation and preventing structural damage compared to Otezla (apremilast), which should be reserved for patients with contraindications to biologics or those preferring oral therapy. 1

Efficacy Comparison

Simponi Aria (Golimumab IV) Advantages

• Achieves higher response rates: TNF inhibitors like golimumab effectively suppress inflammation, leading to disappearance of signs and symptoms and maximal improvement of physical function 1
• Targets remission: Guidelines establish clinical remission/inactive disease as the primary treatment target for inflammatory arthritis, which TNF inhibitors are more likely to achieve 1
• Proven structural protection: While TNF inhibition may not prevent spinal progression in AS, it demonstrates efficacy in preventing peripheral joint damage in RA and PsA 1
• Effective for axial disease: TNF inhibitors are strongly recommended as first-line biologic therapy for psoriatic spondylitis/axial disease, whereas apremilast lacks efficacy for axial manifestations 1
• Sustained long-term efficacy: Safety and efficacy of golimumab are maintained through 5 years of treatment in RA, PsA, and AS 2

Otezla (Apremilast) Advantages

• Oral administration: Convenient once-daily dosing without need for infusions or injections 3, 4
• No immunosuppression: Lower infection risk profile compared to TNF inhibitors 4
• Acceptable safety profile: Most common adverse effects are gastrointestinal (diarrhea, nausea) and headache, which are generally mild to moderate 4
• No monitoring requirements: Does not require routine laboratory monitoring like biologics 4
• Specific niche indications: May be preferred for patients with recurrent infections or contraindications to TNF inhibitors 1

Safety Profile Comparison

Simponi Aria Safety Concerns

• Serious infections: 3.4 events per 100 patient-years, including tuberculosis (0.4/100 patient-years) and opportunistic infections (0.2/100 patient-years) 5
• Malignancy risk: 0.4 events per 100 patient-years 5
• Major adverse cardiovascular events: 0.5 events per 100 patient-years 5
• Concomitant corticosteroid risk: Serious infections more common when combined with low-dose oral corticosteroids 5
• Infusion-related considerations: Requires IV access and infusion center visits every 8 weeks 2

Otezla Safety Advantages

• Lower infection risk: No increased risk of serious infections, tuberculosis, or opportunistic infections compared to biologics 4
• No malignancy signal: Acceptable safety profile without increased malignancy risk 4
• Gastrointestinal effects: Diarrhea and nausea are most common but typically self-limited 4

Clinical Decision Algorithm

Choose Simponi Aria When:

1. Treatment goal is remission or low disease activity in RA, PsA, or AS 1
2. Axial disease is present (psoriatic spondylitis or ankylosing spondylitis) 1
3. Structural damage prevention is priority in peripheral arthritis 1
4. Patient has failed NSAIDs and requires disease-modifying therapy 1
5. Concomitant inflammatory bowel disease is present (monoclonal antibodies preferred over oral agents) 1

Choose Otezla When:

1. Patient has contraindications to TNF inhibitors (active infection, history of recurrent infections, malignancy) 1, 4
2. Patient strongly prefers oral therapy over infusions 1
3. Predominant enthesitis with patient preference for oral therapy or contraindications to biologics 1
4. Mild to moderate disease activity where remission is not the immediate target 4
5. Patient has failed or is intolerant to conventional DMARDs but biologics are not yet indicated 4

Specific Disease Considerations

Rheumatoid Arthritis

• Simponi Aria is preferred: TNF inhibitors demonstrate superior efficacy in achieving remission and preventing radiographic progression 1
• Otezla role: Reserved for patients unable to take DMARDs or biologics 4

Psoriatic Arthritis

• Simponi Aria first-line for moderate-severe disease: TNF inhibitors recommended over oral small molecules for treatment-naive patients 1
• Otezla acceptable for mild disease: May be used in treatment-naive patients who prefer oral therapy or have contraindications to TNF inhibitors 1
• Tofacitinib preferred over apremilast: When choosing oral agents, JAK inhibitors demonstrate superior efficacy 1

Ankylosing Spondylitis/Axial Disease

• Simponi Aria strongly recommended: TNF inhibitors are the only biologics with proven efficacy for axial manifestations 1
• Otezla not effective: IL-12/23 inhibitors (similar mechanism class) failed to show efficacy in axial spondyloarthritis trials; apremilast should not be used for axial disease 1

Common Pitfalls to Avoid

• Do not use apremilast for axial disease: It lacks efficacy for spinal inflammation and will delay appropriate treatment 1
• Do not underestimate infection risk with Simponi Aria: Screen for latent tuberculosis and hepatitis B before initiating therapy 5
• Do not combine Simponi Aria with high-dose corticosteroids: This increases serious infection risk significantly 5
• Do not reserve biologics too long: Early TNF inhibitor use in inflammatory arthritis leads to better long-term outcomes 1
• Do not expect structural protection from apremilast: It provides symptomatic relief but does not prevent joint damage 4

Cardiovascular Risk Considerations

• Both agents require cardiovascular risk assessment: Patients with RA, PsA, and AS have elevated cardiovascular risk requiring annual assessment 1
• Adequate disease control reduces CV risk: TNF inhibitors and methotrexate demonstrate best evidence for lowering cardiovascular risk through inflammation control 1
• NSAIDs and COX-2 inhibitors carry CV risk: Use cautiously in patients with documented cardiovascular disease or risk factors 1

Perioperative Management

Simponi Aria

• Withhold before elective surgery: Schedule surgery when next dose would be due (approximately 8 weeks after last infusion) 1, 6
• Resume after wound healing: Typically 14 days postoperatively when sutures removed and no infection present 6

Otezla

• Continue through surgery: Can be continued perioperatively without increased infection risk 6